Danish big pharma Novo Nordisk has been given the go-ahead for its star weight loss drug, Wegovy (semaglutide), in patients with metabolic dysfunction-associated steatohepatitis (MASH) who have ...

Fosun and Expedition make $645m licensing deal for respiratory drug Fosun Pharma will retain the rights to develop, manufacture and commercialise XH-S004 in some specific regions.

Lilly first to opt for confidential reimbursement price in Germany This will be the first time the option has been taken up since it was introduced at the beginning of 2025, under the Medical Research ...

Trump targets bolstering of US emergency drug reserve The White House has blamed the Biden administration for failing to advance domestic production or fill the reserve.

AbbVie is investing $195m to strengthen domestic API production, with the expansion of its manufacturing plant in North Chicago, Illinois.

RFK Jr’s mRNA funding halt signals “shift in US public health” The health secretary has halted the development of 22 mRNA vaccine projects by BARDA while stopping all future schemes.

The UK MHRA has granted marketing authorisation for Takeda’s dengue virus vaccine candidate, Qdenga (Dengue Tetravalent Vaccine).

The FDA has approved a label expansion to Teva’s Ajovy in certain children and adolescents, making it the first migraine prevention drug of its kind in the age group.

The history of ALS stretches back to the 19th century, but despite decades of research and drug trials, a cure remains elusive.

Pfizer shares rise 3% after upping profit forecast for 2025 Staving off headwinds from Ibrance generic competition, Pfizer’s Q2 earnings surpassed analyst estimates.

Insmed wins FDA approval for future blockbuster Brinsupri Brinsupri becomes the first bronchiectasis therapy while ushering in a new class of DPP1 inhibitors.

Gilead's PrEP Yeztugo is set to become the pharma's star asset, with GlobalData forecasting of just under $5bn in 2031.